Epigenica Funding Round

6/30/2025

Venture Equity

$2,200,000

Undisclosed

This funding will accelerate the development and commercialisation of Epigenica's flagship products, including the already available EpiFinder Genome and upcoming EpiFinder Global and EpiFinder cNUC kits.

Private & Independent

Biopharmaceutical

Nanna Svartz väg 2
Solna, 171 65
Sweden

Undisclosed

Epigenica was formed in 2020 after Simon Elsässer Ph.D., then an Assistant Professor at the Karolinska Institute, was approached by a large pharmaceutical company to find or build a new technology that could generate quantitative data on a large scale, fast and cost-effectively. Finding nothing available on the market that fit the bill and realizing the potential of technology under development in his laboratory, he teamed up with Mohamad Takwa, Ph.D., an experienced entrepreneur and scientist, to tackle the problem. They quickly secured funding and set off to develop state-of-the-art products for epigenetic screening. With headquarters in Solna, Sweden, Epigenica has secured seed funding from Almi Invest and Scale Up Life Science, and is rapidly commercializing a family of epigenetic profiling kits based on its patented chip technology.